ANNX Annexon, Inc.
Annexon, Inc. (ANNX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -27.9% since its last earnings release on November 9, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Annexon, Inc.
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.